It is a long-acting amylin analog that reduces appetite. The combination Cagrilintide 5mg + Semaglutide 5mg represents a next-generation, research-stage approach to metabolic health, uniting amylin and GLP-1 agonist pathways to potentially enhance weight loss and glucose control beyond single-agent effects.